Tumor associated glycoprotein-72 (TAG-72), a pancarcinoma antigen, was initially identified in cancer tissues by its immunoreactivity to a monoclonal antibody B72.3. In this study, we have analyzed the expression and localization profiles of TAG-72 in ovarian cancer tissue samples of different stages and histological subtypes by immunohistochemistry using a second generation high affinity monoclonal antibody CC49. We have also studied the expression of TAG-72 in ovarian cancer cell lines by confocal microscopy and immunoblot analyses. A correlation between TAG-72 expression and localization with patients' prognosis was also analyzed using Kaplan-Meier analysis. Eighty eight percent of the ovarian cancer tissue samples (n = 43) showed immunoreactivity with CC49 antibody. The expression of TAG-72 in advanced stage cancer tissues (mean composite score = 3.7) was significantly higher (p = 0.035) compared to the early stage tumors (mean composite score = 2.3). However, no significant correlation of TAG-72 was observed with histological tumor types. A marginal correlation of TAG-72 staining with patients' survival was observed. Interestingly, the membrane localization of TAG-72 in tumors was significantly (p = 0.0082) associated to the poor clinical outcome, while cytoplasmic staining was correlated significantly to a better prognosis (p = 0.0051). Immunoblot analysis demonstrated the expression of TAG-72 in three ovarian cancer cell lines (OVCAR3, SB247 and COV362.4). In conclusion, the tumor-specific expression of TAG-72 and its association with disease stage indicate its potential as a marker for effective disease management and targeted cancer therapy.

Original languageEnglish (US)
Pages (from-to)247-257
Number of pages11
JournalCancer Letters
Issue number2
StatePublished - Jun 28 2007


  • Diagnosis
  • Ovarian cancer
  • Prognosis
  • TAG-72
  • Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis'. Together they form a unique fingerprint.

Cite this